The century-old outdoor apparel brand, famed for pioneering the quilted down jacket, is preparing to close its North American retail footprint while its licensing and e-commerce operations continue under new management.
The FDA has issued a complete response letter for Aquestive Therapeutics' sublingual epinephrine film Anaphylm, citing concerns over packaging and user instructions. The company aims to address the issues and resubmit its application by the third quarter of this year.
Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
As major indices climb, investors are sifting through economic crosscurrents to find resilient tech innovators. We examine three companies—Veracyte, monday.com, and Zeta Global—whose strategic moves and financial momentum position them for potential growth.
Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
The U.S. manufacturing sector snapped a year-long contraction in January, with two key surveys pointing to a sharp rebound in production and new orders. However, the recovery comes alongside heightened input costs and lingering concerns over tariffs and inventory build-up.
Fosun International's stock has tumbled over 14% in the last 90 days, reigniting the debate over the Chinese conglomerate's true worth. With shares trading at HK$4.12 against a widely cited fair value of HK$5.77, analysts are divided on whether this is a moment of market overreaction or a sign of deeper structural challenges.
Restaurant Brands International (RBI) has formed a joint venture with private equity firm CPE, ceding majority control of Burger King's China operations in a deal aimed at turbocharging growth. The partnership targets a more than tripling of restaurants to over 4,000 by 2035, leveraging local expertise and capital.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Fourth-quarter earnings for S&P 500 companies are significantly outperforming expectations, led by robust growth in industrial and tech sectors, as investors await a busy week of corporate results and key economic data.
AIGH Capital Management has liquidated its entire position in semiconductor firm MaxLinear, a move that coincides with the chipmaker's recent strong quarterly earnings report, raising questions about the fund's strategy.
The century-old outdoor apparel brand, owned by Catalyst Brands, is preparing a Chapter 11 filing that could shutter its North American store network, while its e-commerce and wholesale operations are set for a transfer to new licensee Outdoor 5.
The Adecco Group is making a strategic pivot into higher-margin HR and talent consulting through its LHH brand, a move analysts say could reshape its valuation narrative amid a challenging stock performance history.
French authorities have demanded 1.7 billion euros from Uber for unpaid payroll taxes, alleging the ride-hailing giant misclassified drivers as independent contractors to avoid employer obligations, a report reveals.
An Atlanta law firm is investigating Home Depot's planned layoff of nearly 800 Georgia workers, exploring a potential class-action lawsuit over whether the company violated federal notification laws.
As United Parcel Service executes a strategic overhaul focused on profitability over volume, its financials reveal a nascent but promising trend, leading some investors to see a potential rebound on the horizon despite recent stock declines.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
